Sign in
CompletedNo phase

Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients

Key facts

Who runs it
Centre Hospitalier Universitaire de Nīmes
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
230 people enrolled
Started
1 Jan 2024
Ended
31 Dec 2025
Type of study
Observational
Treatments tested
  • Molecular epidemiology of the collection
  • Study of the resistome of the S. pettenkoferi population
  • Study of the virulome of the S. pettenkoferi population
  • Study of the resistance profiles of all S. pettenkoferi isolates
  • Selection of strains for in-depth phenotypic study
  • Selection of strains (n=3) for the virulence study
Record updated
25 September 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi

Who cannot take part

  • Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. Although studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no studies have focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is unknown, yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory and 80% of the bacteria present are in biofilms.It is essential to understand the mechanisms governing these bacterial interactions and establish the true pathogenic potential of these bacteria. Recently, the Nîmes team showed that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. SP165 could not only produce biofilm, but could also survive in human blood, human keratinocytes and murine and human macrophages. It also caused significant embryonic mortality in a zebrafish model. A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated that there were two predominant clones with different virulences. Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.

Treatments tested

  • Molecular epidemiology of the collection
  • Study of the resistome of the S. pettenkoferi population
  • Study of the virulome of the S. pettenkoferi population
  • Study of the resistance profiles of all S. pettenkoferi isolates
  • Selection of strains for in-depth phenotypic study
  • Selection of strains (n=3) for the virulence study

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
Record updated
25 September 2026